CDK
Les inhibiteurs des kinases dépendantes des cyclines (CDK) sont des composés qui bloquent l'activité des CDK, un groupe de kinases protéiques qui régulent le cycle cellulaire, la transcription et d'autres processus cellulaires. Les CDK sont activées par leur liaison aux cyclines, et leur activité est cruciale pour la progression des cellules à travers les différentes phases du cycle cellulaire. Inhiber les CDK peut arrêter la division cellulaire, entraînant un arrêt du cycle cellulaire et l'apoptose, en particulier dans les cellules cancéreuses où les CDK sont souvent dysrégulées. Les inhibiteurs de CDK sont largement utilisés dans la recherche sur le cancer et ont un potentiel thérapeutique dans le traitement de divers cancers. Chez CymitQuimica, nous offrons une sélection complète d'inhibiteurs de CDK de haute qualité pour soutenir vos recherches sur le contrôle du cycle cellulaire, le cancer et le développement thérapeutique.
500 produits trouvés pour "CDK"
Trier par
Degré de pureté (%)
0
100
|
0
|
50
|
90
|
95
|
100
CDK4/6-IN-23
<p>CDK4/6-IN-23 (Compound 42) is a potent and selective inhibitor of CDK4/6, displaying an IC50 of 11 nM for CDK6. This compound significantly activates immune cells and enhances IL-3 production. In mice undergoing 5-FU chemotherapy, CDK4/6-IN-23 demonstrates dual bone marrow protection and immunomodulatory effects.</p>Formule :C32H34FN7O4Couleur et forme :SolidMasse moléculaire :599.655[pSer2, pSer5, pSer7]-CTD TFA
<p>Substrate '[pSer2, pSer5, pSer7]-CTD (TFA)' for CDK7 phosphorylates RNA Pol II CTD at ser2, 5, 7.</p>Formule :C98H138F3N21O39Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :2291.25dCeMM3
CAS :<p>dCeMM3 is a glue degrader that induces ubiquitination and degradation of cyclin K by promoting CDK12-cyclin K interaction with CRL4B ligase.</p>Formule :C14H11ClN4OSDegré de pureté :98.48% - 99.41%Couleur et forme :SolidMasse moléculaire :318.78CPS2
CAS :<p>CPS2: potent, selective PROTAC CDK2 degrader. IC50=24nM, targets acute myeloid leukemia research.</p>Formule :C38H42N12O10S2Couleur et forme :SolidMasse moléculaire :890.94PROTAC CDK9 degrader-8
<p>PROTAC CDK9 Degrader-8 (Compound 21) is a potent degrader of CDK9 with an IC50 of 0.01 μM, utilized in cancer research [1].</p>Formule :C44H52Cl2N10O7Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :903.85PROTAC CDK9 degrader-7
CAS :<p>PROTAC CDK9 degrader-7 is a proteolysis-targeting chimera (PROTAC) specifically designed to target and mediate the degradation of Cyclin-Dependent Kinase 9 (</p>Formule :C43H50Cl2N8O9Couleur et forme :SoildMasse moléculaire :893.813-Methylthienyl-carbonyl-JNJ-7706621
CAS :<p>Potent CDK inhibitor 3-Methylthienyl-carbonyl-JNJ-7706621, IC50: CDK1=6.4nM, CDK2=2nM, GSK-3=0.041μM; moderate on CDK4/VEGF-R2/FGF-R2.</p>Formule :C14H14N6O3S2Couleur et forme :SolidMasse moléculaire :378.43CDK7-IN-7
CAS :<p>CDK7-IN-7: Selective CDK7 inhibitor, IC50 < 50 nM (Patent CN112661745A).</p>Formule :C20H20BrF3N6O2Couleur et forme :SolidMasse moléculaire :513.319CDK7-IN-2 hydrochloride hydrate
CAS :<p>CDK7-IN-2 HCl hydrate is a potent, specific CDK7 enzyme inhibitor with significant anti-cancer effects.</p>Formule :C26H42ClN7O4Couleur et forme :SolidMasse moléculaire :552.12YKL-5-124 TFA
CAS :<p>YKL-5-124 TFA is a potent CDK7 inhibitor (IC50: 53.5 nM), more than 100x selective over CDK9/2, not active on CDK12/13, and disrupts the cell cycle.</p>Formule :C30H34F3N7O5Couleur et forme :SolidMasse moléculaire :629.63IV-361
CAS :<p>IV-361, an orally active and selective CDK7 inhibitor with a Ki value of less than or equal to 50 nM, demonstrates potent anti-cancer activity (US20190256531A1</p>Formule :C23H32FN5O2SiCouleur et forme :SolidMasse moléculaire :457.625EGFR/CDK2-IN-2
<p>EGFR/CDK2-IN-2 (compound 6a) serves as a dual inhibitor targeting both EGFR and CDK-2, exhibiting IC50 values of 19.6 nM and 87.9 nM, respectively.</p>Formule :C49H32N12O2S2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :884.99Multi-target kinase inhibitor 2
<p>Compound 5K (Multi-target kinase inhibitor 2) is a multi-targeted kinase inhibitor demonstrating activity against EGFR, Her2, VEGFR2, and CDK2 with IC50 values</p>Degré de pureté :98%Couleur et forme :Odour SolidCDK-IN-12
CAS :<p>CDK-IN-12 (Example 20), a CDK inhibitor, effectively inhibits CDK4/6, demonstrating IC50 values below 20 nM [1].</p>Formule :C26H29FN6OSCouleur et forme :SolidMasse moléculaire :492.61CDK2/PIM1-IN-1
<p>CDK2/PIM1-IN-1 is an inhibitor of the kinases CDK2 (IC50: 0.27 μM) and PIM1 (IC50: 0.67 μM). It can induce apoptosis (cell death) and reduce the expression of TNF-α, which promotes tumors. CDK2/PIM1-IN-1 exhibits antitumor activity.</p>Couleur et forme :Odour SolidLSN3106729 hydrochloride
CAS :<p>LSN3106729 hydrochloride, an Abemaciclib metabolite, is a CDK-inhibiting antitumor PROTAC CDK4/6 degrader.</p>Formule :C25H29ClF2N8OCouleur et forme :SoildMasse moléculaire :531.00Abemaciclib metabolite M18
CAS :<p>Abemaciclib M18 (LSN3106729), a potent CDK inhibitor with antitumor action, used in a PROTAC to degrade CDK4/6.</p>Formule :C25H28F2N8ODegré de pureté :98%Couleur et forme :SolidMasse moléculaire :494.54XY028-133
CAS :<p>XY028-133 is a PROTAC-based CDK4/6 degrader for the study of tumors.</p>Formule :C53H67N11O7SDegré de pureté :97.11%Couleur et forme :SolidMasse moléculaire :1002.23BSJ-04-132
<p>Selective Cdk4 degrader. Degrades Cdk4 in Molt-4 cells, with no effect on Cdk6 levels. Displays cereblon-dependent degradation.</p>Couleur et forme :Liquid(1S,3R,5R)-PIM447 dihydrochloride
<p>(1S,3R,5R)-PIM447 (dihydrochloride) an inhibitor of PIM(IC50 of 0.095 μM for Pim1, 0.522 μM for Pim2 and 0.369 μM for Pim3).</p>Formule :C24H25Cl2F3N4ODegré de pureté :98%Couleur et forme :SolidMasse moléculaire :513.38EGFR/CDK2-IN-3
<p>EGFR/CDK2-IN-3 (compound 4b) serves as a dual inhibitor targeting both EGFR and CDK-2, exhibiting IC50 values of 71.7 nM and 113.7 nM, respectively.</p>Formule :C30H20N6OSDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :512.58BLINK15
<p>BLINK15 is a blood-brain barrier-permeable Cdk5 inhibitor. It reduces CDK5 activity in CDK5/p35 (IC50= 29.34 nM) and CDK5/p25 (IC50= 12.08 nM) complexes. Additionally, BLINK15 exhibits antidiabetic and neuroprotective effects. It lowers blood glucose levels in type 2 diabetes (T2D) mice, enhances cognitive abilities, and diminishes neurodegenerative lesions.</p>Couleur et forme :Odour SolidCDK9 degrader-1
<p>CDK9degrader-1 is a selective CDK9 degrader (DC50: 0.4073 µM). It recruits ATG101 to initiate the autophagy-lysosome pathway and forms autophagosomes by recruiting LC3, which then fuse with lysosomes to degrade CDK9 and its partner protein, Cyclin T1 (DC50: 1.215 µM). CDK9degrader-1 induces caspase 3-mediated apoptosis and exhibits antitumor activity in a mouse HCT116 xenograft model.</p>Formule :C32H34Cl2N6O4Couleur et forme :SolidMasse moléculaire :637.56LL-K8-22
<p>LL-K8-22: potent CDK8/cyclin C degrader; DC50 ~2.5μM; hinders STAT1 phosphorylation; curbs E2F/MYC cancer pathways; for TNBC study.</p>Formule :C37H43N5OCouleur et forme :SolidMasse moléculaire :573.77Kinase Inhibitor Library
<p>A unique collection of 2720 kinase inhibitors/regulators for high throughput screening and high content screening for drug discovery in kinase related diseases;</p>Couleur et forme :Odour SolidCDK2/4-IN-1
<p>CDK2/4-IN-1 (compound B-4a) serves as both a CDK2/4 inhibitor and a microtubule polymerization inhibitor, making it useful in cancer research.</p>Couleur et forme :Odour SolidCDK9/EZH2-IN-1
CAS :<p>CDK9/EZH2-IN-1 is a dual-target inhibitor of CDK9 and EZH2 with IC50 values of 83.9 nM and 108.6 nM, respectively. It induces apoptosis and causes DNA double-strand breaks (DSB). Additionally, CDK9/EZH2-IN-1 inhibits the proliferation of MKN45, MDA-MB-453, and SW620 cancer cells, with respective IC50 values of 136.3 nM, 171.3 nM, and 315.7 nM.</p>Formule :C47H59N11O4S2Couleur et forme :SolidMasse moléculaire :906.17CDK12-IN-6
CAS :<p>CDK12-IN-6, a pyrazolotriazine, strongly inhibits CDK12 (IC50 1.19 μM at 2 mM ATP), but not CDK2/Cyclin E or CDK9/Cyclin T1 (both IC50 >20 μM).</p>Formule :C20H21F2N9Couleur et forme :SolidMasse moléculaire :425.448PROTAC CDK9 degrader 4
CAS :<p>PROTAC CDK9 degrader 4 is a CDK9 degrader that targets transcriptional regulation and has potential anticancer activity.</p>Formule :C43H56N10O5Couleur et forme :SolidMasse moléculaire :792.97PP-C8
<p>PP-C8: PROTAC CDK12-Cyclin K degrader with DC50s 416/412 nM; synergizes with PARP inhibitor against TNBC.</p>Formule :C43H51FN12O7Couleur et forme :SolidMasse moléculaire :866.94CDK4/6-IN-11
CAS :<p>CDK4/6-IN-11 is a potent PROTAC CDK4/6 degrader.</p>Formule :C43H49N11O7Couleur et forme :SolidMasse moléculaire :831.92CDK1-IN-2
CAS :<p>CDK1-IN-2 (cdk1 inhibitor 2) is a CDK1 inhibitor with IC50 of 5.8 μM.</p>Formule :C17H11ClN2ODegré de pureté :98.53%Couleur et forme :SoildMasse moléculaire :294.73TG003
CAS :<p>TG003 is a Clk1/Sty inhibitor that inhibits Clk1 and Clk4, suppresses cancer cell growth, and induces apoptosis.</p>Formule :C13H15NO2SDegré de pureté :99.46%Couleur et forme :SolidMasse moléculaire :249.33Ribociclib hydrochloride
CAS :<p>Ribociclib hydrochloride is a highly specific CDK4/6 inhibitor (IC50: 10 nM and 39 nM, respectively).</p>Formule :C23H31ClN8ODegré de pureté :98%Couleur et forme :SolidMasse moléculaire :471NCT02
CAS :<p>NCT02 degrades cyclin K, leading to CCNK and CDK12 degradation, potentially aiding metastatic CRC research.</p>Formule :C17H16N2O2SCouleur et forme :SolidMasse moléculaire :312.39CDK5-IN-3
CAS :<p>CDK5-IN-3 is a selective and potent CDK5 inhibitor that inhibits CDK5/p25 and CDK2/CycA, and can be used in the study of cancer.</p>Formule :C22H26N4ODegré de pureté :98.21%Couleur et forme :SolidMasse moléculaire :362.47Palbociclib-d8
CAS :<p>Palbociclib-d8 (PD 0332991 D8) is the deuterated form of Palbociclib. Palbociclib is a CDK inhibitor that inhibits CDK4 and CDK6.</p>Formule :C24H21D8N7O2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :455.58LDC4297
CAS :<p>LDC4297 (LDC044297) is a potent and selective CDK7 inhibitor.</p>Formule :C23H28N8ODegré de pureté :98.25%Couleur et forme :SolidMasse moléculaire :432.52GP-82996
CAS :<p>GP-82996 (CINK4) inhibits CDK4/6; IC50s: 1.5 μM (CDK4/D1), 5.6 μM (CDK6/D1), 25 μM (Cdk5/p35); triggers U2OS cancer cell apoptosis.</p>Formule :C27H32N6ODegré de pureté :99.94%Couleur et forme :SolidMasse moléculaire :456.58NU6102
CAS :<p>NU6102 is a CDK2 inhibitor with antitumor activity against CDK1/cyclinB, CDK1/CDK2, CDK4, DYRK1A , PDK1, and ROCKII, and it can be used to study rectal cancer.</p>Formule :C18H22N6O3SDegré de pureté :99.76%Couleur et forme :SolidMasse moléculaire :402.47Palbociclib hydrochloride
CAS :<p>Palbociclib hydrochloride is the salt form of Palbociclib, a selective and orally available CDK4 and CDK6 inhibitor for breast and hepatocellular carcinoma.</p>Formule :C24H31Cl2N7O2Degré de pureté :99.89%Couleur et forme :SolidMasse moléculaire :520.46(E/Z)-Zotiraciclib hydrochloride
CAS :<p>(E/Z)-Zotiraciclib ((E/Z)-TG02) hydrochloride is a potent inhibitor of CDK2, JAK2, and FLT3.</p>Formule :C23H25ClN4OCouleur et forme :SolidMasse moléculaire :408.93FMF-04-159-2
CAS :<p>FMF-04-159-2 is a potent covalent CDK14 & CDK2 inhibito and is able to reduce α-Syn aggregation in neurons, and inhibits TNBC cancer progression.</p>Formule :C28H30Cl3N7O5SDegré de pureté :96.57%Couleur et forme :SolidMasse moléculaire :683.01Ribociclib-d6
CAS :<p>Ribociclib-d6 is a deuterated compound of Ribociclib (LEE011) for isotope tracing.Ribociclib is an orally available CDK4/6 inhibitor with antitumor activity.</p>Formule :C23H30N8OCouleur et forme :SolidMasse moléculaire :440.57CDK9-IN-1
CAS :<p>CDK9-IN-1 is a selective and potent CDK9 inhibitor with antiviral activity used in the study of PRRSV infections.</p>Formule :C26H21N5O4SDegré de pureté :98.52%Couleur et forme :SolidMasse moléculaire :499.54Longdaysin
CAS :<p>Longdaysin is an inhibitor of CK1α and CK1δ (IC50s: 5.6/8.8 μM). It also can inhibit ERK2 (IC50: 52 μM).</p>Formule :C16H16F3N5Degré de pureté :99.97%Couleur et forme :SolidMasse moléculaire :335.33Atuveciclib
CAS :<p>Atuveciclib Racemate is an oral CDK9 inhibitor with a 13 nM IC50, targeting P-TEFb/CDK9 selectively.</p>Formule :C18H18FN5O2SDegré de pureté :98.8%Couleur et forme :SolidMasse moléculaire :387.43DRB
CAS :<p>DRB is a nucleoside analog that inhibits several carboxyl-terminal domain (CTD) kinases including casein kinase II (IC50 range of 4-10 μM)</p>Formule :C12H12Cl2N2O4Degré de pureté :99.46% - 99.83%Couleur et forme :White To Off-White Crystalline SolidMasse moléculaire :319.14TC11
CAS :<p>TC11 (1H-Isoindole-1,3(2H)-dione, 5-amino-2-[2,6-bis(1-methylethyl)phenyl]-TC11) is a potent inhibitor of tumor cell proliferation and an inducer of apoptosis</p>Formule :C20H22N2O2Degré de pureté :97.86%Couleur et forme :SolidMasse moléculaire :322.4Cdk5 Substrate acetate
<p>Cdk5, a serine/threonine kinase active in neurons, phosphorylates proteins like histone H1; its synthetic substrate has a Km of 5 µM.</p>Formule :C55H103N15O14Degré de pureté :96.21%Couleur et forme :SolidMasse moléculaire :1198.5
